Join us for our latest seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU.

​For any medicine marketed in Europe, a key commercial consideration is the timing of generic or biosimilar market entry. Protection from competition is derived from two principal sources: intellectual property rights (patents and Supplementary Protection Certificates), and regulatory exclusivities. The new EU Pharma Package introduces changes to the regulatory exclusivities that are available.

​In this seminar, Dr Andrew Wells (Partner and Head of the HGF Chemistry & Pharmaceutical Group) will explain the proposed reforms and discuss what they mean for both innovator and generic pharmaceutical companies.

​We look forward to welcoming you to the seminar.

​Please note photography may be taken throughout the event to be used for marketing material, if you would prefer not to be in any photographs, please contact us via [email protected]

​About the hosts:

​HGF is one of Europe's leading intellectual property firms, supporting innovative businesses across the life sciences sector, from early-stage spinouts and venture-backed companies to multinational organizations. Through HGF100, we bring together founders, investors and industry leaders to share insights, build connections and support the growth of the life sciences ecosystem.